focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 62.00
Bid: 61.00
Ask: 63.00
Change: 0.50 (0.81%)
Spread: 2.00 (3.279%)
Open: 61.50
High: 62.00
Low: 61.50
Prev. Close: 61.50
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

16 Oct 2008 07:00

RNS Number : 9607F
Oxeco PLC
16 October 2008
 



16 October 2008

Oxeco Plc (the "Company" or the "Group" )

Interim financial report for the six months ended 31 July 2008

Chairman's Statement

I am pleased to report on your Group's performance for the six months ended 31 July 2008. 

Oxeco Plc is a holding and management company, specialising in the development and growth of trading businesses within the technology and science sectors. The Company currently has one subsidiary, Oxray Ltd, which was acquired in June 2007 and is a start up business which aims to become a leading provider of molecular structure determination services to both industry and academic institutions. 

The unaudited consolidated loss before tax for the Group in six months to 31 July 2008 amounted to £105,000 compared to £3,000 for the comparable period from incorporation on 17 October 2006 to 31 July 2007. Consolidated net assets at 31 July 2008 amounted to £4.77 million including cash balances of £2.64 million versus net assets of £4.93 million and cash balances of £2.81 million a year earlier at 31 July 2007. The cash outflow for the Group during the six months to 31 July 2008 amounted to £120,000 and cash balances continue to be managed prudently, with tight cost control.

Oxray's primary objectives are the development of novel X-ray crystallography structure determination software and the provision of a small-molecule X-ray crystallography structure service. The service uses a web portal behind which the company can work to maximise the extent to which the service can be automated. The Company offers standardised response times to its customers but also offers market premium services such as a fast-response and extended scientific reporting suitable to support customers' patent applications. Oxray expects to complete the initial development of it's X-ray crystallography structure determination software within the next six months and will then focus on the marketing of the service and the establishment of a solid customer base.

Oxeco Plc is well capitalised and I am confident that your Company will continue to make considerable progress in its development during the second half of the year despite turbulent financial marketsYour Directors are continuing to evaluate a range of new commercial and acquisition opportunities which they believe fulfil the Company's original objectives of investing in the technology and science sectors, and especially those which are complimentary to the existing Group activities.

Finally I would like to conclude by thanking our employees and management for their hard work and support in the growth and development of the Group in the period.

Jussi Westergren

Executive Chairman

Contact:

Michael Bretherton

Oxeco plc

www.oxecoplc.com

+44 (0) 207352 8989

 Ray Zimmerman/Jonathan Evans

Zimmerman Adams International Limited

+44 (0) 207 060 1760

Daniel Briggs

Religare Hichens, Harrison plc

+44 (0) 207 382 7776

 

 

 

 

OXECO PLC

CONDENSED CONSOLIDATED INCOME STATEMENT

FOR THE SIX MONTHS TO 31 JULY 2008

 
Notes
Six months to 31 July
2008
(Unaudited)
Period to
31 July
2007
(Unaudited)
Period to
31 January
2008
(Audited)
 
 
£000
£000
£000
 
 
 
 
 
Revenue
 
6
-
7
Administrative expenses
 
(188)
(95)
(243)
 
 
 
 
 
Operating Loss
 
(182)
(95)
(236)
 
 
 
 
 
Interest receivable
 
77
92
178
 
 
 
 
 
Loss before tax
 
(105)
(3)
(58)
 
 
 
 
 
Taxation
2
3
(5)
 
 
 
 
 
Loss for the period
 
(102)
(3)
(63)
Earnings per share Basic and Diluted
3
(0.02p)
(0.00)p
(0.01)p
 
 

 

Comparative figures comprise the period from incorporation on 17 October 2006 to 31 July 2007 and from the period from incorporation on 17 October 2006 to 31 January 2008.

The loss for the period arises from the Group's continuing operations.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHS TO 31 JULY 2008

 
Share Capital £000
Share Premium £000
Retained Loss £000
Total Equity £000
At 17 October 2006
Issue of shares
600
4,500
5,100
Expenses of issue of shares
(167)
(167)
Loss for the period
(3)
(3)
At 31 July 2007
600
4,333
(3)
4,930
Loss for the period
-
-
(60)
(60)
At 31 January 2008
600
4,333
(63)
4,870
Loss for the period
-
-
(102)
(102)
At 31 July 2008
600
4,333
(165)
4,768
 
 

OXECO PLC

CONDENSED CONSOLIDATED BALANCE SHEET

AS AT 31 JULY 2008

 
Notes
31 July 2008
31 July 2007
31 January 2008
 
 
(Unaudited)
(Unaudited)
(Audited)
 
 
£000
£000
£000
ASSETS
Non-current assets
 
 
 
 
Property, plant and equipment
 
1
1
2
Intangible assets - goodwill
 
2,120
2,120
2,120
Total non-current assets
 
2,121
2,121
2,122
 
 
 
 
 
Current assets
 
 
 
 
Trade and other receivables
 
38
16
29
Cash and cash equivalents
 
2,641
2,816
2,761
Total current assets
 
2,679
2,832
2,790
 
 
 
 
 
TOTAL ASSETS
 
4,800
4,953
4,912
 
 
 
 
 
LIABILITIES
 
 
 
 
Current Liabilities
 
 
 
 
Trade and other payables
 
(30)
(23)
(37)
Current taxation
 
(2)
-
(5)
 
 
 
 
 
TOTAL LIABILITIES
 
(32)
(23)
(42)
 
 
 
 
 
NET ASSETS
 
4,768
4,930
4,870
 
 
 
 
 
EQUITY
 
 
 
 
Issued capital
3
600
600
600
Share premium
 
4,333
4,333
4,333
Revenue reserve
 
(165)
(3)
(63)
TOTAL EQUITY SHAREHOLDERS’ FUNDS
 
4,768
4,930
4,870
 
 

 

Approved by the Board and authorised for issue on 16 October 2008.

J P Westergren M A Bretherton

Chairman Finance Director

OXECO PLC

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

FOR THE SIX MONTHS ENDED 31 JULY 2008

 
Six months to
31 July 2008
Period to
31 July 2007
Period to
31 January 2008
 
(Unaudited)
(Unaudited)
(Audited)
 
£000
£000
£000
OPERATING ACTIVITIES
 
 
 
Operating loss before taxation
(182)
(95)
(236)
Depreciation of property, plant and equipment
1
-
-
Increase in trade and other receivables
(9)
(16)
(29)
Decrease in trade and other payables
(7)
(30)
(15)
Net cash outflow from operations
(197)
(141)
(280)
 
 
 
 
INVESTING ACTIVITIES
 
 
 
Purchase of property, plant and equipment
-
-
(2)
Acquisition of subsidiaries
-
(100)
(100)
Cash and bank in subsidiaries at acquisition
-
32
32
Net cash outflow from investing activities
-
(68)
(70)
 
 
 
 
FINANCING ACTIVITIES
 
 
 
Proceeds from issue of share capital
-
3,100
3,100
Expenses of issue of share capital
-
(167)
(167)
Interest received
77
92
178
Net cash inflow from financing activities
77
3,025
3,111
 
 
 
 
(DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS
(120)
2,816
2,761
 
 
 
 
Cash and cash equivalents at start of period
2,761
-
 
 
 
 
CASH AND CASH EQUIVALENTS AT END OF PERIOD
2,641
2,816
2,761
 
 

Comparative figures comprise the period from incorporation on 17 October 2006 to 31 July 2007 and from the period from incorporation on 17 October 2006 to 31 January 2008.

OXECO PLC

NOTES TO THE CONDENSED FINANCIAL STATEMENTS 

FOR THE SIX MONTHS ENDED 31 JULY 2008

1) SIGNIFICANT ACCOUNTING POLICIES

Basis of preparation

The interim financial statements of Oxeco Plc are unaudited condensed consolidated financial statements for the period for the six months period to 31 July 2008. These include unaudited comparatives for the period from incorporation on 1October 2006 to 31 July 2007 together with audited comparatives for the period from incorporation on 17 October 2006 to 31 July 2007.

The condensed consolidated financial statements have been prepared under the historic cost convention and incorporate the financials of Oxeco Plc for the period and its subsidiary undertaking from the date of acquisition.

The accounting policies adopted are consistent with those followed in the preparation of the Group's annual financial statements for the period ended 31 January 2008.

The condensed consolidated financial statements do not constitute statutory accounts. The statutory accounts for the period to 31 January 2008 have been reported on by the Company's auditors and have been filed with the Registrar of Companies. The report of the auditors was unqualified and did not contain a statement under section 237(2) or 237(3) of the Companies Act 1985.

2) TAXATION

The accrued tax charge for the six month period is based on an estimated effective tax rate of nil, after allowance for utilisation of tax losses brought forward in subsidiaries and prior year adjustments, (period to 31 July 2007: effective tax rate nil, period to 31 January 2008: effective tax rate 8.6 per cent.).

3) LOSS PER SHARE

Basic loss per share is based on the net loss for the period of £102,000 attributable to equity holders of the parent divided by the weighted average number of ordinary shares in issue during the period of 600,000,000, (period to 31 July 2007: loss £3,000 divided by the weighted average number of 353,658,537 shares; period to 31 January 2008: loss £63,000 divided by the weighted average of 456,050,955 shares). Fully diluted earnings per share are the same as basic earnings per share.

4) SHARE CAPITAL
Number
£’000
Authorised ordinary shares of 1p:
 
 
 
 
 
At 31 July 2007, 31 January 2008 and 31 July 2008
1,000,000,000
1,000
 
 
 
Allotted, issued and fully paid ordinary shares of 1p:
 
 
 
 
 
At 31 July 2007, 31 January 2008 and 31 July 2008
600,000,000
600
 
 

5) RELATED PARTY TRANSACTIONS

During the period the Company entered into the following transactions with Ora Capital Partners Plc (ORA) which as at 31 July 2008 held 45.25% of the Company's issued share capital.

 
Six months to
31 July
 2008
Period to
31 July
2007
Period to
31 January 2008
 
(Unaudited)
(Unaudited)
(Audited)
 
£000
£000
£000
Management consultancy fees charged by ORA
6
7
18
 

 

During the period the Company's wholly owned subsidiary, Oxray Ltd, borrowed £nil (31 July 2007: £100,000)  from the Company for working capital purposes. The loan is non-interest bearing, is repayable on demand and the outstanding balance at 31 July 2008 was £200,000 (31 July 2007: £100,000).

6) INTERIM FINANCIAL REPORT

A copy of this interim report will be distributed to shareholders and is also available on the Company's website at www.oxecoplc.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR ILFLDISLELIT
Date   Source Headline
17th Oct 20194:27 pmRNSHolding(s) in Company
17th Oct 20197:00 amRNSTrading Update
15th Oct 20193:27 pmRNSHolding(s) in Company
3rd Oct 20197:00 amRNSDermaPure Product Line Extension Launched
10th Sep 20197:00 amRNSUnaudited Interim Results
28th Aug 20197:00 amRNSAppointment of CFO
15th Aug 20197:00 amRNSAdditional manufacturing capacity secured
1st Aug 20197:00 amRNSDirectorate Change
8th Jul 20195:03 pmRNSHolding(s) in Company
20th Jun 20192:23 pmEQSHardman & Co Research: Tissue Regenix (TRX): Credit facilities expand cash runway to 2021
7th Jun 20192:55 pmRNSIssue of Equity and Total Voting Rights
4th Jun 20197:00 amRNSNotice of AGM
4th Jun 20197:00 amRNSSecures Credit Facilities of up to $20m
4th Jun 20197:00 amRNSAnnual Results for the year ended 31 December 2018
21st May 20197:00 amRNSCEO to return to full time duties
10th Apr 20197:20 amEQSHardman & Co Research: Tissue Regenix (TRX): Expanded GPO coverage secured
4th Apr 20197:26 amRNSExpands US GPO coverage for DermaPure
18th Feb 20197:00 amRNSChange of Adviser
6th Feb 201911:05 amRNSSecond Price Monitoring Extn
6th Feb 201911:00 amRNSPrice Monitoring Extension
4th Feb 20197:00 amRNSTrading Update
17th Dec 201811:56 amEQSHardman & Co Research: Tissue Regenix (TRX): 2018 in review: foundations laid for osteobiologics
6th Dec 20187:00 amRNSInterim Management Change
13th Nov 20187:00 amRNSPan European distribution agreement with Arthrex
29th Oct 20187:00 amRNSGareth Jones commences position as CFO
14th Sep 20187:16 amEQSHardman & Co Research: Tissue Regenix (TRX): Strategy delivering growth above expectations
3rd Sep 20187:00 amRNSUnaudited Interim Results
2nd Aug 201810:10 amEQSHardman & Co Research: Tissue Regenix (TRX): 1H'18 preview: organic plus inorganic growth
2nd Aug 20187:00 amRNSNotice of Interim Results
4th Jul 20187:00 amRNSAppointment of CFO
25th Jun 20187:00 amRNSHTA License granted and UK distribution Agreement
21st Jun 20187:10 amRNSTRX BioSurgery wins GPO Supplier Horizon Award
18th Jun 20187:00 amRNSIssue of Equity
24th May 201812:12 pmRNSResult of AGM
2nd May 20187:00 amRNSTRX BioSurgery GPO agreement with Premier, Inc.
27th Apr 20187:00 amRNSPosting of Annual Report and Notice of AGM
24th Apr 20187:00 amRNSDermaPure manufacturing at CellRight Facility
19th Apr 20183:29 pmRNSHolding(s) in Company
5th Apr 20187:17 amEQSHardman & Co Research: Tissue Regenix (TRX): CellRight hits the right note
26th Mar 20187:00 amRNSAnnual results for period ended 31 December 2017
16th Mar 20183:40 pmRNSPublication of Financial Results
8th Mar 20187:15 amRNSHardman & Co: Full-year 2017 - what to look for
6th Mar 20187:00 amRNSLong term distribution agreement with Arthrex, Inc
26th Feb 20187:00 amRNSNotice of Results
26th Feb 20187:00 amRNSLaunch of BioSurgery and new distributor agreement
2nd Feb 20187:00 amRNSIssue of Equity
22nd Dec 20179:30 amRNSIssue of Equity
1st Dec 20177:00 amRNSDirectorate Change
1st Dec 20177:00 amRNSIssue of Equity
2nd Nov 20177:00 amRNSAppointment of CEO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.